Stocks and Investing
Stocks and Investing
Tue, January 17, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Joseph Schwartz Maintained (ASND) at Buy with Increased Target to $163 on, Jan 17th, 2023
Joseph Schwartz of SVB Leerink, Maintained "Ascendis Pharma A/S" (ASND) at Buy with Increased Target from $148 to $163 on, Jan 17th, 2023.
Joseph has made no other calls on ASND in the last 4 months.
There are 6 other peers that have a rating on ASND. Out of the 6 peers that are also analyzing ASND, 0 agree with Joseph's Rating of Hold.
These are the ratings of the 6 analyists that currently disagree with Joseph
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $177 on, Tuesday, January 3rd, 2023
- Vikram Purohit of "Morgan Stanley" Maintained at Buy with Increased Target to $148 on, Tuesday, November 15th, 2022
- Andreas Argyrides of "Wedbush" Maintained at Buy with Increased Target to $164 on, Monday, November 14th, 2022
- David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $163 on, Thursday, November 3rd, 2022
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Increased Target to $130 on, Thursday, November 3rd, 2022
- Paul Choi of "Goldman Sachs" Initiated at Strong Buy and Held Target at $174 on, Thursday, October 20th, 2022
Contributing Sources